Objective: The purpose was to evaluate the effect of combined administration of TXA on total blood loss, hidden blood loss, drain output, cost effectiveness and periprosthetic infection rate in patients undergoing unilateral primary knee arthroplasty. Sakarya Med J, 2018, 8(2):423-431 )
Introduction
Primary total knee arthroplasty (TKA) is associated with perioperative blood loss ranging from 800-1700 ml. 1-4 Allogenic blood transfusion mostly utilizes for perioperative anemia after primary TKA, although it includes disease transmission, risk of ABO incompatibility, immunologic and allergic reactions and additional cost. Numerous blood conservation methods are used to reduce the risks of allogenic transfusion, including controlled hypotension, regional anesthesia, autologous blood transfusion, intraoperative blood salvage, and the use of erythropoietin and antifi brinolytic agents. But there is no certain consensus about the preferred technique .1,5-7 Antifi brinolytic agents block the lysine-binding sites on plasminogen, so plasminogen activation to plasmin is prevented. 8, 9 Tranexamic acid (TXA) and epsilon aminocaproic acid or aprotinin are mostly used antifi brinolytic agents. Among these drugs, TXA have been used more frequently for blood conservation method because it is cheaper, safer and more potent. Other antifi brinolytic drugs and fi brin spray have been also used to reduce blood loss, however aprotinin is associated with increased mortality and may lead to allergic reactions and precious aminocaproic acid has been associated with hypotension, cardiac arrhythmias, myopathy, and rhabdomyolysis, and less effective than TXA. Moreover, TXA is more potent and cheaper than fi brin sealants. 5, 6, 9 In the literature, there are a lot of systemic reviews and meta-analysis about effi cacy of TXA in primary TKA. In these studies, TXA was used in intravenous (IV), topical and combined administration forms. Numerous dosages and administration ways of TXA have been described in these studies. 6, [10] [11] [12] [13] The main attention of the previous studies was to reduce total blood loss, which was usually measured by volume of drainage fl uid, however hb concentration in drain and simultaneous venous sample is not the same. Hb concentration in the drainage can be less than in simultaneous samples of venous blood. 1, 14, 15 Also, blood accumulates in the joint and around thigh after TKA, called as hidden blood loss, and it is considered that the hb concentration of hidden blood loss is higher than in the drains. 14, 15 Indeed, these used TXA methods have reduced blood loss by decreasing the total drainage output and did not effectively affect the hidden blood loss with respect to drain output. 1, 3, 16 Patients used TXA administrations have had lower post-operative hemoglobin than expected. 13 Additionally, in previous studies demonstrated that hidden blood loss also can cause increasing hematom formation around the knee joint and these conditions can lead to have a higher incidence of periprosthetic infection. [17] [18] [19] [20] So we consider that the TXA method for using for reduction of total blood loss must reduce not only drainage fl uid but also hidden blood loss. In our study, we combined both topical and continuous up to 24 hours IV administration of TXA. The aim of our study was to show the combined administration of TXA provided to reduce signifi cant blood loss, but also reduce signifi cant hidden blood loss.
Materials and Methods
All of the patients who undergone unilateral primary knee arthroplasty between May 2014 and December 2014 at Ufuk University Faculty of Medicine, Department of Orthopaedic Surgery included in our study were admitted with a diagnosis of primary gonarthrosis. The exclusion criteria were; usage of anticoagulant medication within pre-operative seven days, acute sepsis history, a coagulation defect or abnormal coagulation profi le, cerebrovascular accident, myocardial infarction, atrial fi brillation, history of deep vein thrombosis (DVT) or pulmonary embolus (PE), preo- Fifty-eight patients meeting the aforementioned criteria were included in our retrospective study.
We compared 29 cases performed without the application of TXA to 29 cases performed with the application of TXA (250 mg Tranexamic acid, 5% Ampule, 5 ml, Actavis Drugs Inc., Istanbul, Turkey). Informed consents were obtained from all patients. The same senior surgeon operated all of these patients. The Ethics Committee of Ufuk University has permitted this study (date/document number: 04012017/9).
Our TXA protocol consisted of three stages. First, 15 mg/kg of TXA were given as infusion over 10 minutes before infl ation of tourniquet, secondly, two grams of TXA completed up to 100 cc with normal saline to irrigate wound before closure of arthrotomy and, eventually 7.5 mg/kg of TXA was given as infusion 3 hourly for 24 hours and hemowac drain was removed at 24 h postoperative after the given last dosage. Patients were operated under general anesthesia or spinal and/or epidural aneshtesia by applying a thigh pneumatic tourniquet infl ated to 300 mmHg in supine position. A midline incision and medial parapatellar arthrotomy were used. All patients were undergone unilateral knee cemented knee prosthesis by NexGen LPS-Flex (Zimmer Inc., Warsaw, IN, USA) (posterior cruciate ligament sacrifi cing design) fi xed bearing knees prosthesis with no patellar resurfacing. Immediately after component placement and irrigating by normal saline, two grams of TXA completed up to 100 cc with normal saline was used. After fi ve minutes, the irrigate was suctioned. Routine closure was performed with hemowac drains. Compressive dressings were applied from toe to thigh, like Jones' dressings. Surgical hemowac drain was kept in negative pressure after 30 minutes keeping closed. 4.000 IU of low molecular weight heparin (LMWH) (Clexane, Aventis Inc., Istanbul, Turkey) was given all patients subcutaneously 6 hours postoperatively for the spinal anesthesia group or immediately after surgery for the general anesthesia group.
Physical examination for DVT screening was applied to all patients routinely. Total blood counts were seen on postoperative day 0, 1, 2 and 3. Preoperative and postoperative day 3 serum hemoglobin levels were compared, and blood loss was assessed according to formula of Nadler and Good. 1, 21 Patients were considered for blood transfusion if they had symptomatic hypotension, palpitations, and shortness of breath, lightheadedness or a postoperative hemoglobin level less than 7 g/dl. All patients were mobilized after removing the hemowac drains. All patients were discharged from the hospital with anticoagulant treatment on postoperative day 3. Routine 4.000 IU of LMWH was given 10 days for anticoagulant treatment if there were no additional risk factors.
Patients were checked on postoperative 3rd. and 6th. week for DVT screening and physical examination.
Statistical analysis of two groups was achieved using the Student's t-test, Mann-Whitney U test, continuity correction (Yates) test, Fisher's exact test, and Pearson correlation coeffi cient method.
The parameters suitability for normal distribution was assessed by Shapiro Wilks test. The confidence level was 95% and signifi cance was set at p<0.05. Analyses were achieved using SPSS v.15
for Windows (SPSS Inc., Chicago, IL, USA) software.
Results
In this study, 58 patients who underwent primary TKA, was divided into two groups. patients who did not. There were no statistical differences in preoperative baseline values between two groups in terms of, age, gender, weight, height, body mass index (BMI), side, serum hemoglobin(hgb) and hematocrit (htc) level, total blood volume, platelet count, INR, and aPTT.
Also, no statistical differences were detected between two groups for length of hospitalization, type of anesthetic method utilized, duration of surgery, DVT and PE incidence during postoperative period, 6th. week postoperative follow up active range of motion levels. The demographic characteristic could be seen in Table 1 . Postoperative hgb and htc levels were detected to be signifi cantly lower in the non-TXA group (average, 10.38 g/dl, 31.6%,) respectively as compared to the TXA group (average 11.66 g/dl, 34.54%) respectively (p=0.001). Estimated blood loss, hidden blood loss, and drain output were detected to be signifi cantly higher in the non-TXA group (average, 3291.62 ml, 2510.76 ml, 780.86 ml respectively) as compared to the TXA group (average, 698 ml, 484.66 ml, 213.79 ml respectively) (p=0.001). Transfusion rate was signifi cantly lower in TXA group (average, 0.03) as compared to the non-TXA group (average, 0.66) (p=0.001). The blood bank costs were found to be signifi cantly higher (average, 37.2 $) in the non-TXA group as compared to the TXA (average, 1.6 $). And average pharmacy cost of TXA was 5.7 $ in the TXA group. The total direct cost, which included sum of given transfusion units and TXA, was also signifi cantly higher in the non-TXA group (average, 37.2 $) as compared to the TXA group (average, 7.3$) (p=0.001). This was average 29.9 $ savings per case in the TXA group. Patients' statistical fi ndings could be seen in Table 2 .
We have not seen any deep vein thrombosis or any pulmonary embolous cases in any group as complication. We have not detected any surgical wound complications or infections and any hypersensitivity reactions or adverse effects of TXA. 
Discussion
Blood loss reducing management of unilateral primary TKA has been a popular issue recently. 1, 2, 5, 6, 9-11, 13, 22 Allogenic blood transfusion has been used commonly for postoperative anemia following TKA. In many institutions, the erythrocyte suspensions are routinely arranged preoperatively for TKA. 9, 22, 23 But this method has numerous well-known side effects and is considered not being a cost effective method for replacement of blood loss after surgery. 6, [23] [24] [25] Numerous medical managements also have been used for reducing blood loss. 8-10, 13, 26, 27 TXA has been used as one of the medical treatments for reducing blood loss because It can be found easily, it is cheap, potent drug and safer in use for reducing blood loss. 1, 8, 10, 13, 24, 25 There are numerous published literatures on TXA's role, dose and administration way. But there is
no consensus on what dose and administration way are effective for reducing blood loss after TKA. 6, [10] [11] [12] In our study, TXA was administered both in a topical and systemic way. In the literature, bolus dosage for TXA ranged between 15-30 mg/kg and was given before infl ation or defl ation of the tourniquet. [10] [11] [12] [13] We applied bolus from 15 mg/kg TXA 10 minutes before infl ation of the tourniquet.
In the literature, topical dosage was ranged between 0.25-3 g of TXA within normal saline to irrigate wound before the closure of arthrotomy or after wound closure. It was given through to the drain and drain was clamped varying minutes. 5, 6, 10, 12, 13 We prepared two grams of TXA completed up to 100 cc with normal saline to irrigate wound before the closure of arthrotomy. Eventually, 7.5 mg/ kg of TXA was given as infusion per 3 hours period for the fi rst 24 hours. Because blood levels of TXA are reduced by half from 2 to 3 h after intravenous administration. 28 Zhao-Yu6 et al reported their results of meta-analysis about intra-articular TXA injection during total knee arthroplasty. They analyzed 647 patients from 6 studies and reported that intraarticular injection of TXA in patients undergoing TKA may reduce total blood loss and the need for blood transfusions. Gandhi11 et al reported that their metaanalysis results about TXA in both total knee and hip arthroplasty. In that study, various dosages of TXA were used and they reduced the amount of total blood loss, however in those metaanalysis, the amount of hidden blood loss was not mentioned. Good1 et al were analyzed 51 patients' outcomes. 24 patients TXA was applied intravenously and 27 patients were not. According to that study, TXA decreased total blood loss by nearly 30%, drainage volume by nearly 50%, thus reducing transfusion needs. But hidden blood loss was not affected as same as drainage volume by TXA. Consequently, hidden blood loss can be as much as drainage volume.
Therefore, they stated that it must be highly questionable to use the "volume of drainage fl uid'' as a measure of blood loss in primary TKA. 1 In our study, we detected that hidden blood loss was more than drainage volume in both groups, however hidden blood loss in the TXA group is much less than non-TXA groups and the difference is signifi cant. It showed us that; preoperative intravenous application, topical irrigation and 3 hourly postoperative intravenous regimen of TXA up to 24 hours were enough to reduce both the blood loss and hidden loss. But the most important fi nding for our study was that the proportion of reduction in hidden blood loss was affected than proportion of reduction in drainage volume. In the literature, rates of postoperative hematoma formation with minor or major were reported between 0% to 10% of patients and many of them are healed spontaneously with conservative treatment and some of them required surgical intervention because of infection. [17] [18] [19] [20] Negative effect of hidden blood loss could be seen in the study of Galat 18 et al in which they evaluated 17.784 primary total knee arthroplasties during the 23 years. They reported that patients requiring surgical intervention within thirty days from the index primary total knee arthroplasty because of postoperative hematoma having a 10.5% risk for deep infection and 12.3% risk for major re-operation up to two years. Parvizi 20 et al reported the their results in which septic failure following primary or revision total hip or total knee arthroplasty had a risk of hematoma confi guration 12.6 times more than their control group. That way, they revealed a relationship between excessive anticoagulation causing hematoma in the surgical site and the development of periprosthetic infection. Although we didn't see any infection in both groups, we agree with relationship between hematoma and periprosthetic infection and we also think that we make contribution for reduction of periprosthetic infection due to hematoma following the total knee arthroplasty via reducing hidden blood loss with our combined method.
Besides, reducing blood transfusion rates, cost benefi t analysis should be checked for determining true incomes of using TXA. Decreasing blood transfusion rates because of using of TXA provides signifi cant reduction in average cost on per patient in the TKA. The average pharmacy-drug cost was higher in TXA group than non-TXA group, zero, 5.7 $ respectively. However total cost should be calculated by summing up pharmacy costs, blood costs, and hospitalization costs all together. In our study, the length of stay was nearly same, but total blood usage was higher in non-TXA group.
When average total cost was calculated, non-TXA cost was signifi cantly higher than TXA group, 
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The small sample size is the limitation of this study. Although combined TXA method was effective for total blood loss and hidden blood loss we don't know whether only topical method or systemic method are effective or enough for reduction for hidden blood loss or total blood loss. We think that four groups composed of only topical group, only systemic group, both systemic and topical group and control group are suitable to reveal of TXA effects on total blood loss and hidden blood loss, however we had not so much patients and an institutional review board approval to compare groups used like these protocols. Direct correlation between amount of hidden blood loss and periprosthetic infection rate may be objectively evaluated in larger patient groups that be given and not given such a combined TXA protocols. Thus, it may reveal whether TXA administration indirectly reduces periprosthetic infection rate by decreasing hidden blood loss. Lack of number of patient is an important limitation for our study in order to evaluate that potential effect of TXA protocol.
Conclusion
We have detected that combined topical and continuous up to 24 hours intravenous administration of TXA reduced the total blood loss and decreased drainage volume, as well as reducing the hidden blood loss. Thus, postoperative transfusion necessity reduced, and allogenic transfusion complications may be prevented. Also, periprosthetic infection rate could be reduced this combined method by reduced hidden blood loss. This combined method is cost-effective and easier, but the most important side is that it doesn't increase thromboembolic complications.
